Gamida Cell Ltd (GMDAQ)
| Market Cap | 1.76M |
| Revenue (ttm) | 1.78M |
| Net Income (ttm) | -63.00M |
| Shares Out | 110.05M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,784 |
| Open | n/a |
| Previous Close | 0.0160 |
| Day's Range | n/a |
| 52-Week Range | 0.0080 - 0.0250 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GMDAQ
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Ma... [Read more]
News
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge ® (omidubicel-onlv)
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge ® (omidubicel-onlv), with the delivery of six units in 2023...
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its f...
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel...
Gamida Cell Actively Pursuing Strategic Alternatives
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it is actively pursuing strategic al...
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced it will present new data on its FDA ...
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought lead...
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will presen...
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
Company continues to advance launch, reports initial revenue from Omisirge ® (omidubicel-onlv)
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data further characterize the mechanism for Gamida Cell's proprietary nicotinamide (NAM) technology's expansion and enhancement of cells Data further characterize the mechanism for Gamida Cell's propr...
Gamida Cell to Report Third Quarter 2023 Financial Results
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its fi...
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new early data in 10 patients with CD20 positive non-...
Gamida Cell Issues Update on Israel Operations
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today issued an update on its operations in Israel. “We remain profou...
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Off...
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that it will be presenting at the Society for Immunot...
First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the first patient has received a stem cell trans...
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highl...
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today provided a business update and reported financial results for t...
Gamida Cell to Report Second Quarter 2023 Financial Results
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results f...
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell's Omisirge® (omidubicel-onlv)
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the publication in press of a prospective sub-study o...
STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER
Veteran Oncology Researcher to Guide Investment in Breakthrough Cancer Treatments LOS ANGELES , July 10, 2023 /PRNewswire/ -- Stand Up To Cancer® (SU2C) today announced that Julian Adams, Ph.D., a lon...
Gamida Cell To Host Investor Day
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, will host an Investor Day on Thursday, June 29, 2023 beginning at 8 a...
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commer...
Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting Gamida Cell's ...